CURRICULUM VITAE

Robert E. Dupuis, Pharm.D., FCCP

PERSONAL INFORMATION Address – Home: 205 Kenilworth Place Chapel Hill, NC 27516 Office: Division of Pharmacotherapy & Experimental Therapeutics UNC Eshelman School of Pharmacy University of North Carolina at Chapel Hill CB# 7569, 3213 Kerr Hall Chapel Hill, North Carolina 27599-7569 Contact: (919) 966-6194; (919) 962-0644 FAX EMAIL: re_dupuis@unc.edu EDUCATION

Doctor of Pharmacy State University of New York at Buffalo Buffalo, New York June 1982

Bachelor of Science in Pharmacy Northeastern University June 1979 CERTIFICATION

Board Certification in Pharmacotherapy Board of Pharmaceutical Specialties May 1991 – December 2013 LICENSURE

North Carolina (License number 09828) June 1985 - present

PROFESSIONAL EMPLOYMENT

May 2013 – present Clinical Professor of Pharmacy UNC Eshelman School of Pharmacy University of North Carolina at Chapel Hill June 1995 – April 2103 Clinical Associate Professor of Pharmacy

UNC Eshelman School of Pharmacy University of North Carolina at Chapel Hill

June 1995 – present Clinical Specialist in Solid Organ Transplantation Department of Pharmacy UNC Hospitals

May 1989 – May 1995 Assistant Professor of Pharmacy School of Pharmacy University of North Carolina at Chapel Hill June 1985 – May 1989 Instructor School of Pharmacy

University of North Carolina at Chapel Hill

June 1984 – June 1985 Clinical Instructor School of Medicine State University of New York at Buffalo Buffalo, New York

July 1982 – June 1985 Clinical Coordinator in Medicine and Pharmacokinetics Buffalo General Hospital Buffalo, New York October 1982 – June 1985 Clinical Instructor School of Pharmacy State University of New York at Buffalo Buffalo, New York June 1979 – June 1980 Hospital Pharmacy Resident Moses Cone Memorial Hospital Greensboro, North Carolina ADMINISTRATIVE POSITIONS

2006 – present Director of Clinical Research Fellowship Programs Division of Pharmacotherapy & Experimental Therapeutics UNC Eshelman School of Pharmacy

July 1986 – December 2010 Assistant Director of Toxicology Department of Laboratory Medicine UNC Hospitals 1996 – 2006 Director, Solid Organ Transplant Residency Program

UNC Hospitals June 1994 – September 1995 Director, Clinical Pharmacokinetics Service January 1986 – June 1991 UNC Hospitals

AWARDS AND HONORS

White Coat Speaker 2013 "Instructor or Preceptor of the Year" awarded by the UNC School of Pharmacy Pharm.D. classes: 1987, 1990, 1993, 1995, 1998, 2000, 2001, 2003, 2013, 2015 Fellowship in the American College of Clinical Pharmacy awarded by the American College of Clinical Pharmacy, 2008

“Excellence in Teaching Award” awarded by the UNC School of Pharmacy, 2006, 2007

“Access Award” presented by Learning Disabilities Services, University of North Carolina at Chapel Hill, 2002 “Professional Accomplishment Award” presented by State University of New York at Buffalo School of Pharmacy, 1998

MANUSCRIPTS AND REVIEWS 1. Persky AP, Dupuis RE. An eight year retrospective study in flipped pharmacokinetic courses. Am J

Pharm Educ 2014;78:190

2. Moss MC, Kozlowski T, Dupuis R, Detwiler R, Lee RM, Deyo J. Lithium use for bipolar disorder post renal transplant: Is mood stabilization without toxicity possible? Transplantation 2014;97:23-24.

3. Everson GT, Hoefs JC, Niemann CU, Olthoff KM, Dupuis R, Lauriski S, Herman A, Milne N, Gillespie BW, Goodrich NP, Everhart JE. Functional elements associated with heaptic regeneration in living donors after right hepatic lobectomy. Liver Transplant 2013;19:292-297

4. Guptil JT, Dupuis RE, D’Cruz O. Emerging sub-specialties in neurology: clinical development. Neurology 2013;80:14-7.

5. Winston DJ, 1263-301 Clinical Study Group. Efficacy and safety of maribavir dosing at 100mg twice daily for prevention of CMV disease in liver transplant recipients. A randomized double blind placebo controlled multicenter trial. Am J Transplant 2012;11:3021-3030.

6. Dupuis R, Yuen A, Innocenti F. The influence of UGT polymorphisms as biomarkers in solid organ

transplantation. Clinica Chimica Acta 2012: Feb1 (Epub ahead of print). 7. Alloway RR, Dupuis RE, Garbardi S, Kaiser TE, Taber DJ, Tichy EM, Weimert-Pilch NA. Evolution of

the Role of the Transplant Pharmacist on the Multidisciplinary Transplant Team. Am J Transplantation 2011;11:1576-83.

8. Eisenhart A, Dupuis RE. Pursuing a career in transplant pharmacy. Am J Health Syst Pharm

2008;65:2331-2333. 9. Dupuis RE, Stegall-Zanation J, Dupuis R, Persky AM. Experiences with case-based learning in clinical

pharmacokinetics. Am J Pharm Educ 2008;72:29. 10. Dupuis RE, Persky AM, Use of Case-Based Learning in a Clinical Pharmacokinetics Course. Am J

Pharm Educ. 2008 Apr 15;71(2):29. 11. Dupuis R, Harris M, Gillis K, Gerber D, Fair J. Experience with low dose valganciclovir prophylaxis in

liver transplant recipients. Transplant Proc 2007;39:3266-70. 12. Persky AM, Stegall-Zanation J, Dupuis RE. Student perceptions of the incorporation of games into

classroom instruction for basic and clinical pharmacokinetics. Am J Pharm Educ 2007;71:21. 13. Stern ST, Tallman MN, Miles KK, Ritter JK, Dupuis RE, Smith PC. Gender related differences in

mycophenolate mofetil-induced gastrointestinal toxicity in rats. Drug Metab Dispos 2007;35:449-54.

14. Naderer OJ, Dupuis RE, Heinzen E, Wiwattanawongsa K, Johnson MW, Smith PC. The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil. J Clin Pharmacol 2005;45:219-226.

15. Johnson MW, Dupuis RE, Hollar K, Fair J. Limited dose daclizumab as induction immunosuppression in

pediatric liver transplant recipients. Ped Transplant 2003;7:119. 16. Taber DJ, Malat GE, Fann AL, Dupuis RE. Prediction of vancomycin pharmacokinetics and creatinine

clearance after liver transplantation. Ther Drug Mon 2003;25:67-72.

17. Taber DJ, Fann AL, Malat G, Dupuis RE. Evaluation of estimated and measured creatinine clearances for predicting the pharmacokinetics of vancomycin in adult liver transplant recipients. Ther Drug Mon

003 Feb;25(1):67-72.

18. Malat GE, Dupuis RE, Kassman B, Rhoads JM, Freeman K, Lichtman S, Johnson MW, Gerber D, Andreoni K, Fair J. Tacrolimus-induced pain syndrome in a pediatric orthotopic liver transplant patient. Ped Transplant 2002;6:435-438.

19. Taber DJ, Dupuis RE, Fann AL, Andreoni K, Gerber D, Fair J, Johnson MW, Shrestha R. Tacrolimus dosing requirements and concentrations in living donor liver transplant recipients. Liver Transplantation 2002;8:219-223.

20. Joy MS, Hollar KD, Neyhart CD, Hogan SL, Dupuis RE, Finn WF, Dooley MA. Assessment of risk

factors for bone disease in renal transplant recipients. J Pharm Tech 2002;18:54-62. 21. Dupuis RE, Taber DJ, Fann AL, Lumbert KP. Medical management considerations for patients with

lung transplantation. J Pharm Pract 2001;14:258-276. 22. Wiwattanawongsa K, Heinzen EL, Kemp DC, Dupuis RE, Smith PC. Determination of mycophenolic

acid and its phenol glucuronide metabolite in human plasma and urine by high-performance liquid chromatography. J Chromat B 2001;763:35-45.

23. American College of Clinical Pharmacy Clinical Practice Affairs Committee. Practice guidelines for

pharmacotherapy specialists. A position statement of the American College of Clinical Pharmacy. Pharmacotherapy 2000;20:487-490.

24. Taber D, Dupuis RE, Hollar KD, Stralzka AL, Johnson MW. Drug-drug interaction between

chloramphenicol and tacrolimus in a liver transplant recipient. Transplant Proc 2000;32:660-662.

25. Ciminelli A, Dupuis RE, Williams D, Hollar KD. The role of the pharmacist in a multidisciplinary patient education program on a renal transplant service. Am J Health Sys Pharm 2000;57:767-768.

26. Dupuis RE, Sredzienski ES. Tobramycin pharmacokinetics in patients with cystic fibrosis preceding and

following lung transplantation. Ther Drug Mon 1999;21:161-165.

27. Hollar KD, Scott CS, Dupuis RE. Tobramycin Pharmacokinetics in a Pediatric Patient with Cystic Fibrosis Following Lung Transplantation. J Ped Pharm Pract 1998; 3:110-114.

28. Peckman HJ, Dupuis RE, Sawyer WT, Brouwer KLR, Cross RE. Vancomycin serum concentrations in

patients with renal dysfunction: A comparison of fluorescence polarization immunoassay and the enzyme-multiplied immunoassay technique. Ther Drug Mon 1996;18:647-53.

29. Wire PD, Dupuis RE, Lindley CL, Mohler DD, Bernard SO. Methotrexate disposition in a patient with an

orthotopic neo-bladder with and without a urethral catheter cancer. Pharmacotherapy 1996;16:961-64.

30. Dupuis RE, Cooper A, Rosamond LJ, Campbell-Bright S. Delayed peak lithium concentrations in lithium overdose. Ann Pharmacother 1996;30:356-360.

31. Dupuis RE. Book review: Basic Clinical Pharmacokinetics. Third edition 1994. Ann Pharmacotherapy

1995;29:944.

32. Gunnarsson PS, Sawyer WT, Montague D, Williams ML, Dupuis RE, Caiola SM. Appropriate use of heparin: empiric versus nomogram based dosing. Arch Int Med 1995;155:526-532.

33. Kirk JK, Dupuis RE. Therapeutic approaches to the treatment of hyperlipidemia in the transplant

patient. Ann Pharmacother 1995;29:879-891.

34. Kirk JK, Dupuis RE, Miles M, Gaddy GD, Williams DM, Miranda JM. Salivary Theophylline Monitoring: Reassessment and Clinical Considerations. Ther Drug Mon 1994;16:58-66.

35. Price T, Dupuis RE, Carr B, Stanczyk F, Lobo R, Droegemueller W. Single and multiple dose

pharmacokinetics of a low dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis. Am J Obstet Gynecol 1993;168:1400-6.

36. Miles MV, Miranda-Massari J, Dupuis RE, Mill MR, Zaritsky AL, Nocera M, Lawless ST. Determination

of salivary digoxin with a dry strip immunometric assay. Ther Drug Mon 1992;14:249-54.

37. Miles MV, Zaritsky AL, Lawless St, Mill MR, Nocera MA, Dupuis RE. Digoxin monitoring in critically ill pediatric patients. American College of Clinical Pharmacology Meeting, J Clin Pharmacol 1991;31:851.

38. Dupuis RE, Miranda-Massari J. Anticonvulsants - Pharmacotherapeutic issues in the critically ill.

AACN Clinical Issues in Critical Care Nursing 1991;2:639-656.

39. Roush MK, Dupuis R. Significance of the ciprofloxacin-antacid interaction. DICP, Annals of Pharmacotherapy 1991; 25:473-475.

40. Dupuis R, Lichtman S, Pollack G: Acute valproic acid overdose: Clinical course and pharmacokinetic disposition of valproic acid and metabolites. Drug Safety and Adverse Drug Reactions 1990;5:65-71.

41. Dupuis R, Matzke G, Maddux F, O'Neil M. Vancomycin disposition during continuous arteriovenous

hemofiltration. Clinical Pharmacy 1989;8:371-374.

42. Tennison M, Miles MV, Pollack GM, Thorn MD, Dupuis R: Valproate metabolites and hepatotoxicity in an epileptic population. Epilepsia 1988; 29:543-547.

43. Pleasants R, Sawyer W, Dupuis R: Alterations in population volume of distribution values for

aminoglycosides. Clin Pharm 1986;5:872-873.

44. Dupuis R, Slaughter R: Severe theophylline toxicity. Am J Med 1985;A76-A82.

BOOK CHAPTERS

1. Taber DJ, Dupuis RE. “Solid Organ Transplantation” in Applied Therapeutics: The Clinical Use of Drugs, 10th edition. Lippincott Williams & Wilkins, 2012.

2. Dupuis RE. “Pharmacotherapy of Renal Failure” in PharmPrep. Guide to NaPlex, 4th edition. ASHP

Publications, 2010.

3. Taber DJ, Dupuis RE. “Kidney & Liver Transplantation” in Applied Therapeutics: The Clinical Use of Drugs, 9th edition. Lippincott Williams & Wilkins, 2008.

4. Dupuis RE. “Pharmacotherapy of Renal Failure” in PharmPrep. Guide to NaPlex, 3rd edition. ASHP

Publications, 2007.

5. Taber DJ, Dupuis RE. “Solid Organ Transplantation” in Applied Therapeutics: The Clinical Use of Drugs, 8th edition. Lippincott Williams & Wilkins, 2004.

6. Dupuis RE. “Medical Management of Lung Transplant Recipients” in Respiratory Pharmacotherapy

Reference Guide, 1st edition. 2004.

7. Dupuis RE. “Solid Organ Transplantation” in Applied Therapeutics: The Clinical Use of Drugs, 7th edition. Lippincott Williams & Wilkins, 2001.

8. Dupuis RE. “Solid Organ Transplantation” in Applied Therapeutics: The Clinical Use of Drugs, 6th

edition. Lippincott Williams & Wilkins, 1995.

9. Dupuis RE, Miranda-Massari J. “Dialysis and Renal Transplantation” in Workbook for Clinical Pharmacy and Therapeutics. William and Wilkins, 1992.

10. Matzke GR, Dupuis RE, Frye RF, Luke DR. “Renal Transplant Therapy and Dialysis” in Clinical

Pharmacy and Therapeutics, 5th edition. William and Wilkins, 1992.

11. Dupuis RE. “Bayesian forecasting, pharmacokinetics and therapeutic drug monitoring” in Yearbook of Pathology and Clinical Pathology. Brinkhous KM, Dalldorf FG, Langdell RD, McLendon WW (eds.), 1991.

12. Dupuis R. “Drug Interactions” in Pharmacotherapeutics: Nursing Practice in Progress, M. Matheson

(ed.), 1984. SCIENTIFIC ABSTRACTS

1. Moss M, Dupuis R, Deyo J, Deyo J, Kozlowski T, Lee R. Use of erythropoietin stimulating agents for treatment of anemia in the early post transplant period. Am J Transplant 2014:14;1286.

2. Huang J,, Wheeler M,, Lee R, Zeynep T, Dupuis R, Kozolwski T. Does length of hospital stay and hospital-wide incidence incidence have an impact on C Difficile (CDI) in organ transplant recipients. Am J Transplant 2013:13:343.

3. Wheeler M, Deyo J, Huang J, Lee R, Kozlowski T, Dupuis RE. Incidence, risk factors, response rate in initial therapy for C Difficile in solid organ transplants. Am J Transplant 2013;13:344.

4. Moss M, Dupuis RE, Deyo J, Kozlowski T, Chhay A, Lee RA. Impact of thymoglobulin dosing: is the current approach successfully treating acute cellular rejection in kidney allografts. Pharmacotherapy 2013:33:269.

5. Roshdy D, Baker C, Dupuis R, Deyo J, Analysis of dosing strategies for secondary prophylaxis for prevention of CMV recurrence in solid organ transplantation. Pharmacotherapy 2013;13:270.

6. Deyo JC, Dupuis R, Lee RA, Kozlowski T. Modification of induction in kidney transplants with pre-transplant viral infection or chronic long term immunosuppression. Pharmacotherapy 2012;32:272-3.

7. Nguyen T, Dupuis RE, Deyo J, Lee RA, Kozlowski T, Gerber D. The utilization of mycophenolate concentrations in kidney and liver transplant recipients in a tertiary hospital. Am J Transplant 2012;12 (suppl 3):206.

8. Everson Gt, Hoefs JC, Niemann CL, Olthoff KM, Dupuis R. Functional elements associated with hepatic regeneration in living donors after right lobectomy – a sub-study of the adult to adult living donor liver transplantation cohort (A2ALL) study. Hepatology 2010:4(Suppl):569A.

9. Tallman MN, Ali SY, Gillis KA, Dupuis RE, Miles KK, Ritter J, Smith P. Variability in human UDP-GT

protein expression and activity in duodenum, jejunum, and colon. Drug Metab Rev 2005;37(suppl 2). 10. Stern ST, Tallman MN, Miles KK, Dupuis RE, Ritter J, Smith P. Gender related differences in

mycophenolate mofetil induced GI toxicity in rats. Drug Metab Rev 2005;37(Suppl2).

11. Dupuis RE, VanBeuge D, Conoley R. Effectiveness of low dose valganciclovir in liver transplant recipients. Am J Transplant 2005:4.

12. Johnson M, Salm J, Mciver P, Dupuis RE. Comparative analysis of delayed tacrolimus

immunosuppression +/- antibody induction in orthotopic liver transplant patients with pre-operative renal dysfunction. Am J Transplant 2004:4.

13. Johnson M, Zacks S, McIver P, Russo M, Dupuis RE. Randomized trial of oral ganciclovir plus CMV

immunoglobulin versus oral ganciclovir alone for CMV prophylaxis in liver and kidney transplant recipients Am J Transplant 2004:4.

14. Conoley R, Dupuis R, Fair J. The safety and efficacy of rVIIa in orthotopic liver transplantation. Am J

Transplant 2004:4.

15. Conoley R, Dupuis R, Fair J. The safety and efficacy of rVIIa in orthotopic liver transplantation. Pharmacotherapy 2004:24.

16. Dupuis RE, Williams EE, Hawke RI. CYP450 activity and the acute phase response in healthy donors

after living-donor liver transplantation. Hepatology 2004;40(Suppl 4):561A.

17. Kassman B, Summers K, Johnson M, Conoley R, Dupuis RE. Sirolimus use in pediatric liver transplant recipients. With graft rejection or calcineurin-induced toxicity. Ped Transplant 2004:7:113.

18. Reid C, Dupuis RE, Fann AL, Taber DJ, Johnson MW, Fair J. Evaluation of calcium and vitamin D

supplementation in liver transplant recipients. Am J Transplant 2001;1:421.

19. Thompson T, Zacks S, Salm J, Hollar K. Dupuis RE, Johnson M. Is CMV infection risk factor for FSGS in renal transplant recipients. Transplantation 200;69:s216.

20. Taber DJ, Dupuis RE, Hollar KD, et al. Comparison of CMV prophylaxis and preemptive therapy in liver and kidney transplant recipients. Transplantation 2000;69:s181.

21. Hollar KD, Zacks SL, Dupuis RE, et al. Prevalence of low bone mass and risk factors in patients

awaiting liver transplantation. Transplantation 2000;69:s316.

22. Johnson MW, Salm J, Taber D, Schoots M, Hollar KD, Dupuis RE. Delayed use of tacrolimus in orthotopic liver transplant patients with renal insufficiency. Transplantation 2000;69:s216.

23. Wiwattanawongsa K, Heinzen EL, Dupuis RE, Smith PC. Influence of antibiotics on the disposition of mycophenolic acid in the guinea pig. AAPS 1999;s420.

24. Naderer OJ, Dupuis RE, Wiwattanawongsa K, Campbell BJ, Hege SG, Smith PC, Johnson MW.

Reduction of plasma mycophenolic acid and its glucuronide concentrations with antibiotic treatment. Clin Pharmacol Ther 1999;65:159.

25. Hollar KD, Dupuis RE, Williams DW, Dennis BE, Joy MS. Corticosteroid-induced osteoporosis:

assessment of potential risk and prescribed treatment in organ transplant recipients and patients with pulmonary disease. Int Pharm Abstr 1998.

26. Joy MS, Hollar KD, Neyhard CD, Dooley MA, Hogan SL, Dupuis, RE, Finn WF. Risk factors for steroid

induced bone disease in renal transplantation. Transplantation 1998; 65:150.

27. Smith A, Dupuis R, Gott K. Conversion from Sandimmune to Neoral in stable lung transplant recipients. Pharmacotherapy 1997;17:202.

28. Lee B, Dupuis R, Gott K, Paradowski L, Aris R, Detterbeck F, Egan T. The effect of conversion from

Sandimmune to Neonal on the pharmacokinetics of cyclosporine in lung transplant recipients with cystic fibrosis receiving chronic ketoconazole. Pharmacotherapy 1996;16:516-7.

29. Johnson M, Odell P, Dupuis R, Bunzendahl H, Fair J. The cost effectiveness of conversion of Sandimmune to Neoral in liver transplant recipients. American Society of Transplant Physicians, Dallas, TX, May 1996;18:647.

30. Dupuis RE, Sofowora OO, Finn WF. Prediction of cyclosporine area under the concentration-time

curve using limited sampling strategies. Pharmacotherapy 1994;14:372.

31. Baldwin JE, Dupuis RE, Wire PD. Cyclosporine clearance in patients with and without cystic fibrosis following lung transplantation. Int Pharm Abst 1994;31:2288.

32. Dupuis RE, Wire PD, Sredzienski ES. Tobramycin pharmacokinetics and dosing requirements in

patients with cystic fibrosis preceding and following lung transplantation. Int Pharm Abst 1994;31:2291.

33. Miles MV, Dupuis RE, Miranda-Massari JR, Soucie MP. Digibind interference with FPIA and ELIA digoxin methods. 3rd International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Philadelphia, PA, May, 1993.

34. Miranda-Massari JR, Miles MV, Soucie MJ, Dupuis RE. Comparison of digibind effects of digoxin

concentrations with FPIA and ELIA methods. 21st American College of Clinical Pharmacology Meeting, September 1992. J Clin Pharmacol 1992;32:755.

35. Kirk JK, Dupuis RE, Miles MV, Miranda JR, Williams DM. Relationship between saliva and serum

theophylline concentrations: A comparison of two assays and two saliva stimulation methods. Twenty-first Annual American College of Clinical Pharmacology Meeting. September 1992. J Clin Pharmacol 1992;32:754.

36. Breyer ED, Dupuis RE, Cross RE, Letzow CB, Chapman JF. Development and evaluation of an

optimized HPLC assay for cyclosporine A (CsA) and two major metabolites. American Association of Clinical Chemists Meeting, July 1992. Clin Chem 1992;38:1003.

37. Breyer ED, Dupuis RE, Cross RE, Miranda JR, Chapman JF. Comparison between three types of

specific whole blood cyclosporine A assays. American Association of Clinical Chemists Meeting, July 1992. Clin Chem 1992;38:1003.

38. Kirk JK, Dupuis RE, Miles MV, Williams DM, Miranda JM. Comparison of a dry reagent method with

fluorescence polarization immunoassay for the determination of salivary theophylline concentrations. American College of Clinical Pharmacy Meeting, August 1992. Pharmacotherapy 1992;12:248.

39. Price T, Dupuis RE, Carr B, Stanczyk F, Lobo R, Droegemueller W. Multiple dose pharmacokinetics of

a 35 ug ethinyl estradiol, 1 mg norethindrone oral contraceptive in women with chronic renal failure on peritoneal dialysis. Society for Gynecologic Investigation Meeting, March 1992.

40. Matzke GR, Frye RF, Dupuis RE, Carson SW. Optimization of vancomycin bayesian analysis: Initial

population parameters (IPP) vs Forecasting Program. 12th Annual ACCP Meeting, Minneapolis, MN, August 1991. Pharmacotherapy 1991;11:267.

41. Dupuis RE, Miranda-Massari JR, Miles MV, Soucie M. Serial serum digoxin concentrations in patients

receiving digoxin specific FAB fragments (Digibind): A comparison between FPIA and IMAT. 22nd Annual Southeastern Conference for Postgraduate Pharmacy Education and Training, Athens, GA, April 1991.

42. Price T, Dupuis RE, Pollack G, Mattern W, Stanczyk F, Lobo R, Dotters D, Droegemueller W. Single

dose pharmacokinetics of a 35ug ethinyl estradiol, 1mg norethindrone combination oral contraceptive in women with chronic renal failure on CAPD. Society of Gynecologic Investigation Meeting, Dallas, TX, March 1990.

43. Manning J, Hak L, Dupuis R, Dukes G, Gilligan P. Effect of calcium & urea in peritoneal dialysis fluid

on the in vitro killing of Pseudomonas aeruginosa by tobramycin. ASHP Midyear, Atlanta, GA, December 1989.

44. Hak LJ, Sawyer WT, Pleasants RP, Dupuis RE, Sarver PJ. Relationship between aminoglycoside

dose, serum concentration and changes in serum creatinine over time during routine therapy in a university hospital. American College of Clinical Pharmacy, August 1989. Pharmacotherapy 1989;9:189.

45. Howlet CM, Miles M, Cross R, Tennison M, Greenwood R, Dupuis R. Serum N-

desmethylmethsuximide determination using a modified ethosuximide assay procedure. American Association of Clinical Chemists Meeting, July 1988. Clin Chem 1988;34:1255.

46. Dupuis R, Matzke G, Maddux F, O'Neil M: Vancomycin disposition during continuous arteriovenous

hemofiltration. American Society of Hospital Pharmacists Midyear Clinical Meeting, December 1988. Inpharma 1989;26:543.

47. Pleasants R, Dupuis R, Sawyer W: Determination of tobramycin pharmacokinetic parameters by three

immunoassays. American Society of Hospital Pharmacists Midyear Clinical Meeting, December 1988. Inpharma 1989;26:546.

48. Tennison M, Miles MV, Pollack GM, Dupuis R: Valproic acid metabolites and hepatotoxicity in an epileptic population. American Epilepsy Society Meeting Proceedings, December 1987. Epilepsia 1987;28:627.

49. Dupuis R, Pleasants R, Williams D, Calmes H: Use of a Bayesian program to predict serum

theophylline concentrations in the critically ill patient. American Society of Hospital Pharmacists Midyear Clinical Meeting, December 1986.

OTHER PUBLICATIONS

1. Maldonada AQ, Tichy EM, Rogers CC, Campara M, et al. Assessing pharmacologic and nonpharmacologic risks in candidates for kidney transplantation. Am J Health-Sys Pharm 2015;72;e39-e51. Served as contributing reviewer

2. Mueller EW, Bishop JR, Kannan AO, Kiser YH, et al. ACCP Commentary: Research Fellowship Programs as a Pathway for Training Independent Clinical Pharmacy Scientists. Served a s contributing reviewer

3. Dupuis R. Drug interactions with cyclosporine. NCSHP Newsletter, January 1991.

4. Dupuis R. Drug interference with serum creatinine measurements. NCSHP Newsletter, February 1990. PRESENTATIONS

1. Nutritional Vitamin D in Chronic Kidney Disease Triangle College of Clinical Pharmacy Durham, NC November 2012

2. The Science, the Art, and the Allure of Transplantation: Student Program

American Transplant Congress Annual Meeting Boston, MA June 2012

3. Pharmacokinetic and Drug Interaction Profile of Newer Agents in Hepatitis C

Abbott Laboratories AASLD Transplant Advisory Meeting Boston, MA November 2010

4. Immunosuppression in Solid Organ Transplantation

International Transplant Nurses Society 7th Annual Symposium Chapel Hill, NC 2010

5. Bioequivalence Issues in Transplantation

Triangle Transplant Meeting Chapel Hill, NC February 2009

6. Drug Therapy Challenges in Solid Organ Transplantation

American Association of Pharmacy Technicians National Convention Raleigh, NC August 2008

7. Transplant Pharmacology: Evolving Issues in Solid Organ Transplant

International Transplant Nurses Society 5th Annual Conference Chapel Hill, NC March 2008

8. Transplant Recipient Education Initiatives: Current Perspectives in Transplant Therapy

Astellas Pharmacy National Advisory Meeting Chicago, IL July 2007

9. Current Immunosuppressive Therapy: Current Practice and Trends in Organ Transplantation

UNC School of Nursing Annual Meeting Chapel Hill, NC March 2007

10. Post- Transplant Management of Hepatitis B in Liver Transplant Recipients

Nabi Pharmaceuticals Advisory Board Meeting Baltimore, MD September 2006

11. Future of Transplant Pharmacy Training Programs

National Meeting of Transplant Pharmacy Preceptors Boston, MA July 2006

12. Acute Phase Response and Hepatic Drug Metabolism Activity and Recovery After Living-Donor Liver

Transplantation UNC DPET Seminar Series January 2006

13. Role of Mycophenolic Acid in Kidney Transplantation

UNC Division of Nephrology Transplant Fellows Conference Chapel Hill, NC

October 2005 14. Hepatitis B and C Post-Liver Transplant: Prophylaxis and Treatment Options

National Transplant Coordinators Advisory Board Meeting Chicago, IL August 2005

15. Update on Therapeutic Drug Monitoring of Immunosuppressives in Organ Transplantation

Transplant Education Conference Piedmont Hospital Atlanta, GA July, 2005

16. Induction, Infection after Liver Transplantation

Transplant Seminar, Emory University Hospital Atlanta, GA July 2005

17. Complications of Immunosuppression: Cutting Edge: Advances in Organ Transplantation

UNC School Of Nursing Chapel Hill, NC April 2005

18. Assessment of Hepatic CYP450 Activity During Liver Regeneration Following Living-Donor Liver

Transplantation Colorado Springs, CO June 2004

19. Immunology- An Almost New Frontier in Drug Therapy

North Carolina Association of Pharmacists Annual Convention/Carolina Seminar Research Triangle Park, NC October, 2003

20. New Treatment Approach to Hepatitis C

NCAP Acute Care Practice Forum Greensboro, NC April 2003

21. Long Term Complications of Hyperlipidemia in Solid Organ Transplant Recipients

ACCP Annual Meeting Albuquerque, NM October 2002

22. Update on Immunosuppression in Renal Transplantation

UNC School of Medicine Nephrology Conference Chapel Hill, NC June and August 2002

23. Influence of Liver Regeneration on Drug Metabolism after Living Donor Liver Transplantation

Whistler, BC, Canada, March 2002

24. Living Donor Liver Transplantation and Impact on Drug Therapy

UNC School of Medicine, GI & Hepatology Conference Chapel Hill, NC March 2002

25. Important Issues and Medical Management of Complications in Transplant Recipients

ACCP Annual Meeting Tampa, FL October 2001

26. The Role of Pharmacokinetics in the Management of Immunosuppressives in Organ Transplantation

Fujisawa Regional Meeting Chapel Hill, NC June 2001

27. Overview of Immunosuppressive Protocols in Organ Transplant Recipients

Role of the Pharmacist Marco Island, FL January 2001

28. Cardiovascular Risks Factors: The Role of New Immunosuppressants

ACCP Annual Meeting Los Angeles, CA November 2000

29. The Role of the Transplant Pharmacist

Carolinas Medical Center Charlotte, NC October 1999

30. The New Immunosuppressives in Solid Organ Transplant

UNC Transplant Symposium Chapel Hill, NC September 1999

31. Cyclosporine: Pharmacokinetics & Generic Substitution

UNC Comprehensive Transplant Center’s Kidney Transplant Seminar Chapel Hill, NC August 1999

32. Long Term Complications of Solid Organ Transplant Recipients

American Society of Health Systems Pharmacists Annual Meeting Reno, Nevada June 1999

33. Update: Pharmacotherapy in Solid Organ Transplantation

University of North Carolina Chapel Hill, NC November 1996

34. Cyclosporine: The Old and New

Duke University Medical Center, Department of Pharmacy Conference Durham, NC May 1996

35. Pharmacotherapy in Kidney Transplantation

UNC Ambulatory Care Pharmacy Conference May 1996

36. Drug Interactions Update Area Health Education Center Continuing Education Program Fayetteville, NC

February 1996

37. Pharmacotherapy in the Elderly Area Health Education Center Continuing Education Program Burlington, NC November 1995

38. Tacrolimus

Transplant Recipients International Organization Cary, NC November 1995

39. Medicine After Lung Transplantation

UNC Lung Transplant Support Group Chapel Hill, NC Spring 1996 and Fall 1995

40. Clinical Pearl: Cystic Fibrosis and the Lung Transplant

American Society of Hospital Pharmacists Midyear Meeting Miami, FL December 1994

41. Food and Drug Interactions

Ninth Annual Pharmacy Practice Seminar, UNC School of Pharmacy Wilmington, NC September 1994

42. Therapeutic Drug Monitoring

Eighth annual Pharmacy Practice Seminar, UNC School of Pharmacy Wilmington, NC September 1993

43. Encounters in Solid Organ Transplantation

TCCP Research Triangle Park, NC September 1993

44. Pharmacokinetics in the Critically Ill

Duke University Infectious Disease Update Wilmington, NC September 1993

45. Ten Years of Cyclosporine in Transplantation

Virginia Medical Society Continuing Education Program Danville, VA April 1993

46. Immunosuppressives in Heart Transplantation

UNC Hospitals Department of Nursing Program Chapel Hill, NC November 1992

47. Renal Failure Workshop

Seventh Annual Pharmacy Practice Seminar UNC School of Pharmacy and North Carolina Pharmaceutical Association Wilmington, NC September 1992

48. Pharmacokinetics and Plasmapheresis

Miles Medical Supervisors Meeting, Miles Inc. Raleigh, NC August 1992

49. Pharmacokinetic Considerations in Special Populations

Pediatrics and Geriatrics Glaxo Clinical Pharmaceutical Scientist Curriculum Program, Glaxo Inc. Chapel Hill, NC May 1992

50. Organ Transplantation Update: Pharmacology of Immunosuppression

UNC Hospitals Department of Nursing CE Program Chapel Hill, NC March 1992

51. Therapeutic Use of Monoclonal Antibodies

Glaxo Clinical Pharmaceutical Scientist Curriculum Program Chapel Hill, NC January 1992

52. Inter and Intrasubject Variability in the Pharmacokinetics of Cyclosporine in Renal Transplants at UNC:

Preliminary Analysis Department of Medicine, Division of Nephrology, UNC Chapel Hill, NC October 1991

53. Immunosuppressant Therapy in Transplant Patients

Sixth Annual Pharmacy Practice Seminar, UNC School of Pharmacy and North Carolina Pharmaceutical Association Wilmington, NC September 1991

54. Immunosuppressives in Adult Liver Transplantation

UNC Hospitals Department of Nursing CE Program Chapel Hill, NC September 1991

55. Immunosuppresives in Pediatric Liver Transplantation

UNC Hospitals Department of Nursing CE Program Chapel Hill, NC June, July, August 1991

56. Pharmacokinetics and Pharmacodynamic Changes in the Elderly

Northwest AHEC, Appalachian Geriatric Education Center May 1991

57. Lung Transplantation and the Role of Immunosuppressive Agents

UNC Department of Nursing CE Program Chapel Hill, NC February 1991

58. Immunosuppression in Heart Transplantation

UNC Department of Nursing CE Program Chapel Hill, NC January 1991

59. Bayesian Forecasting and Therapeutic Drug Monitoring

UNC Clinical Pathology Series Chapel Hill, NC June 1990

60. Principles of Antimicrobial Therapy IV: Aminoglycosides and Quinolones

Wake AHEC Raleigh, NC May 1990

61. Antilymphocyte Antibodies (OKT3) in Transplantation

NCSHP Winter Meeting High Point, NC February 1990

62. Antibiotic Drug Dosing in Renal Impairment

Roerig Teleconference Chapel Hill, NC November 1989

63. Immunosuppressives in Organ Transplantation

American Association of Critical Care Nursing Durham, NC November 1989

64. New Approach to Cyclosporine Monitoring & Dosing in Renal Transplants

Nephrology Conference, UNC Hospitals Chapel Hill, NC October 1989

65. Immunosuppressives in Heart Transplantation

UNC Department of Nursing CE Program Chapel Hill, NC October 1989

66. Comparison of Assay Methodologies for Measuring Cyclosporine

Department of Medicine, Division of Nephrology, UNC Chapel Hill, NC March 1989

67. Immunosuppressives in Cardiac Transplantation

Department of Nursing, NCMH, CE Program January 1989

68. Vancomycin Dosing in Critically Ill Patients

Critical Care Grand Rounds, Department of Medicine, UNC Chapel Hill, NC November 1988

69. The Value of Clinical Pharmacokinetic Services

Annual Meeting of the NC American Association of Clinical Chemists (AACC) Chapel Hill, NC September 1988

70. Evaluation of Aminoglycoside Pharmacokinetic Software

Area Health Education Center (AHEC) Continuing Education (CE) Program

Rocky Mount, NC November 1987

71. Pharmacokinetics of Vancomycin and Aminoglycosides

NCMH Department of Laboratory Medicine Continuing Education Program October 1987

72. The Value of Vancomycin Serum Concentrations

NCSHP Annual Fall Meeting Raleigh, NC October 1987

73. New Advances in Drug Therapy

NCSHP Meeting Greensboro, NC September 1987

74. Role of an Active Metabolite in Therapeutic Drug Monitoring

Pharmacy Grand Rounds, NCMH April 1987

75. Pentamidine - An Overview

Pharmacy Grand Rounds, NCMH March 1987

76. Pharmacokinetic Software - the Abbott System

Seminar on Microcomputers, Drug Information and Statistics, NCSHP Meeting Greenville, NC November 1986

77. Blood Collection in Therapeutic Drug Monitoring

North Carolina Society of Hospital Pharmacists (NCSHP) Annual Meeting Clinical Pearls Session Greensboro, NC October 1986

78. The Role of Digoxin Antibody in the Treatment of Digoxin Toxicity

Pharmacy Grand Rounds, NCMH September 1986

79. Therapeutic Drug Monitoring

Clinical Pharmacology Conference, Department of Medicine, UNC Chapel Hill, NC October 1985

80. Theophylline: An Update

Pulmonary Grand Rounds, Department of Medicine, UNC Chapel Hill, NC October 1985

RESEARCH GRANTS AND AWARDS

1. Co-Investigator. Restoration of Hepatic Function in Living Liver Donors: An A-2All Multicenter Ancillary Study. National Institutes of Health. 2005 – 2010. $250,000.

2. Co-Investigator. Adult to Adult Living Donor Liver Transplantation. National Institutes of Health. 2002 – 2009.

$842,000. 3. Principal Investigator. An In Vivo Assessment of Changes in CYP450 Activities During Liver Regeneration

Following Living Donor Liver Transplantation. UNC University Research Grant. 2005 – 2007 $3,720. 4. Principal Investigator. Determination of Cytochrome P450 Activities During Liver Regeneration in Donors and

Recipients Following Living Donor Liver Transplantation. Fujisawa Pharmacy Grant. 2002 – 2005. $20,000. 5. Co-Investigator. The Role of UGTs in Drug Disposition. National Institutes of Health. 2002 – 2006. $875,000.

6. Co-Investigator. Botanical Drug Interactions in HIV: Impact in Glucuronidation. National Center for

Complementary and Alternative Medicine. 2004 – 2006. $250,000.

7. Principal Investigator. The Role of Intestinal UGTs in Drug Disposition. UNC School of Pharmacy Seed Grant. 2000. $5,750.

8. Principal Investigator. Time Dependent Changes in the Pharmacokinetic and Pharmacodynamics of Morphine

and Metabolites in Patients with Trauma and Burn Injuries. UNC Injury Prevention Research Center Grant. 1994. $6,000.

9. Co-Principal Investigator. A Comparative Study of the Pharmacokinetics of Morphine and Its Metabolites in

Patients with End-Stage Renal Disease and In Normal Volunteers. UNC School of Pharmacy Faculty Seed Grant. 1993. $6,000.

10. Principal Investigator. Impact of a Novel Pharmacokinetic Dosing Model for Cyclosporine on Patient

Outcome and Costs in Renal Transplant Patients. ASHP Research and Education Foundation Demonstration Grant. 1989 – 1991. $4,900.

11. Principal Investigator. Pharmacokinetic Profiling of Cyclosporine in Renal Transplant Patients. North

Carolina Memorial Hospital Innovative Research Grant. 1989 – 1991. $35,000.

12. Co-Principal Investigator, Impact of Computerized Pharmacokinetic Forecasting on Practitioner Competency, Kinetic Consultation Activity and Patient Outcome. ASHP Research and Education Foundation Demonstration Grant. 1990 – 1992. $4,900.

13. Principal Investigator, Pharmacokinetic Modeling of Cyclosporine and Role of Metabolites in Renal

Transplantation. UNC Junior Faculty Development Award. 1990 – 1991. RESEARCH CONTRACTS

1. Co-Principal Investigator. A Multicenter Randomized Double-blind Placebo Controlled Multiple Dose Study of the Safety Tolerability and Population of Pharmacokinetics of CMX001 in Post-transplant Subjects with BK Virus Viruria. Chimerix INC. 2008 – 2011. $75,900.

2. Principal Investigator. A Randomized Double-blind Study to Assess the Efficacy and Safety of Prophylactic

Use of Maribavir versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants. ViroPharma INC. 2007 – 2009. $87,000.

3. Principal Investigator. The Pharmacokinetics of Mycophenolate in CF and non-CF Lung Transplant Recipients.

Roche. 1998. $28,300.

4. Principal Investigator. Pharmacokinetics and Pharmacodynamics of Mycophenolate in Liver Transplant Recipients. Roche. 1998. $45,700.

5. Principal Investigator. The Influence of Antibiotics on the Enterohepatic Recirculation of Mycophenolate

Mofetil. UNC Faculty Seed Grant. 1997. $3,200.

6. Co-investigator. Comparison of CMV IVIG and Oral Ganciclovir Versus Oral Ganciclovir Alone for Prophylaxis in Kidney and Liver Transplant Recipients. MedImmune, Inc. 1997.

7. Principal Investigator. The Pharmacokinetics of Cyclosporine Before and After Conversion of Neoral from

Sandimmune in Lung Transplant Recipients With Cystic Fibrosis. Sandoz Pharmaceutical Corporation. 1995. $3,000.

8. Principal Investigator. Survey of Transplant Recipient-Pharmacist Interactions, Sandoz Pharmaceutical

Corporation. 1994. $500.

9. Principal Investigator, Comparison of a Dry Reagent Method with Fluorescence Polarization Immunoassay for the Determination of Salivary and Serum Theophylline Concentrations. Miles Inc. 1992. $4,600.

10. Principal Investigator. Evaluation of Two Immunoassays for the Determination of Salivary and Serum

Digoxin Concentrations in Patients with Renal Failure. Miles Inc. 1992. $5,000.

11. Co-Investigator. Bioavailability Study of Rifampin Suspension and Capsules. Carolina Pharmaceutical Products. 1988.

12. Co-Principal Investigator. Evaluation of Three Different Immunoassays for Determination of Tobramycin

Serum Concentrations. Abbott Laboratories. 1988.

13. Principal Investigator. Evaluation of Theophylline Pharmacokinetic Software in Critically Ill Patients. Abbott Laboratories. 1987.

MENTORING Solid Organ Transplantation Specialty Residency

Solid Organ Transplantation Specialty Residency 1996 – 2005

Year Resident Current Position

2004-2005 Matthew Harris Clinical Specialist in Transplantation, Duke University Medical Center

2003-2004 Derrick Van Beuge Medical Science Liasion, Bristol Myers Squib

2002-2003 Ruthann Conoley Clinical Medical Liason, Pfizer 2001-2002 Greg Malat Clinical Specialist in Transplantation,

Hahnamen Medical Center 2000-2001 Amy Rosenberg Residency Director, Shands Hospital

UFLA 1999-2000 David Taber Clinical Specialist in Transplantation,

MUSC 1998-1999 Andrea Ciminelli Buffalo General Hospital 1997-1998 Kimberly Hollar Medical Science Specialist, Abbott

Labs 1996-1997 Angela Smith Duke University Medical Center

Other Residencies

Other Residents Supervised 1999 – 2010

Year Resident

2010 Lisa Fletcher 2010 Chrissy Teeter 2008 Alex Jenkins 2008 Lyndsey Hoffman 2007 Erin McCann 2006 Marintha Meckley 2006 Rocky Karwa 2004 Theresa Thottananiyil 2004 Sabina Ludy 2003 Jill Henderson 2002 Anita Garcia 2002 Jennifer McIntosh 2001 Walid Al-Shaqua 2000 Casey Williams 1999 Imad Treish

PharmD Clinical Scholars/Honors and Research Elective

Students Supervised on Independent or Honors Research Projects 1999-2012

Year Student Project

2010 – 2012 Thanhhoa Nguyen Utilization of Mycophenolate Concentrations in Kidney & Liver transplant Recipients

2011 – 2012 Andrea Yuen UGTs as Biomarkers in Organ Transplantation

2010 – 2011 Jennifer Byrns Neutropenia in Kidney & Liver Transplant Recipients

2010 Purav Bhatt Pharmacogenomics of Calcinuerin Inhibitors and mTOR inhibitors and Organ Transplantation

2009 – 2010 Tanya Daniels Cytomegalovirus Prophylaxis in High Risk Liver Transplant Recipients

2009 Tracy Rupp Survey of North Carolina Pharmacists Utilization of Pharmacokinetic Software

2009 Brian Murray Vancomycin Dosing Requirements in Mordbidly Obese Patients

2008 – 2009 Mike Hurtik Conversion from Cyclosporine to Tacrolimus

2006 – 2007 James Lagasca Caffeine Metabolism after Living Donor Liver Transplantation

2006 – 2007 Lisa Bendz Thymoglobulin and Basiliximab Induction in Liver Transplant Recipients

2006 – 2009 Shazia Ali UGT1A9 genotype and intestinal metabolism of MPA and Propofol

2005 – 2008 Bridgett Kim Drug Interaction Study of Piperidine & Mycophenolate

2005 – 2008 Lindsay Jacobs Comparison of Two Different Valganciclovir Regimens in Kidney & Liver Transplant Recipients

2004 – 2005 Dale Butterfoss Cyclosporine AUC in Lung Transplant Recipients

2002 – 2004 Kelly Summers Sirolimus Use in Pediatric Liver Transplant Recipients

2000 – 2002 Mayur Patel Mycophenolate Pharmacokinetics in Lung Transplant Recipients

2000 – 2001 Kevin Lumbert Lung Transplantation in Patients in Patients With Cystic Fibrosis

2000 – 2001 Erin Heinzen Mycophenolate and Antibiotic Drug Interactions

1999 – 2000 Cheryl Reid Osteoporosis in Liver & Kidney Transplant Recipients

Fellowship Program

Fellowship Program Primary Advisees 1992 – 2006

Year Fellow Current Position

2006 Kathryn Gillis (TX) Clinical Research Scientist, Novartis Pharmaceuticals

2004 Eric Williams (DD) Associate Attorney at Barnes & Thornburg LLP

2002 Andrew Nelsen (DD) United Therapeutics

2001 Kevin Haynes (DD) Senior Research Investigator, School of Medicine, University of Pennsylvania

1998 Odin Naderer (DD) Director, Infectious Diseases, Discovery Medicine, GlaxoSmithKline

1997 Kimberly Hollar (TX) Clinical Science Manager in Virology, Abbott Laboratories

1997 Kimberly Parnell (DD) Associate Director, Clinical Research, Johnson & Johnson, Pharmaceutical Research & Development

1996 Benjamin Lee (DD) (no information) 1995 Patrick Wire (PK) Director, Global Regulatory Affairs at

GlaxoSmithKline 1992 Jorge Miranda (PK) Professor, School of Pharmacy, University of Puert

Rico

*DD = Drug Development; PK = Pharmacokinetics; TX = Transplantation

Graduate Program – Dissertation (D) or Student (S) Advisory Committees

2014 – present Jason Slizgi (S)

2012 – 2013 Brandon Gufford (S/D) - Chair 2006 – 2013 Christina Won (S/D) 2007 – 2012 Latoya Poole-Griffin (S/D) 2002 - 2006 Melanie Tallman (D) 2003 – 2008 Emily Olson (D)

EDITORIAL SERVICE

Review Board Member Pharmacotherapy (Editorial Board) 2009 – present

Annals of Pharmacotherapy (Editorial Board - Transplant section) 2003 – 2014

Reviewer and Contributor Therapeutic Drug Monitoring 2011 – present

Current Opinions in Molecular Therapeutics 2011 ASHP PharmPrep 2005 – present PSAP Clinical Algorithms Handbook 2000-2003 Journal of Pharmacy Practice 1999-2002 Pharmacotherapy Self-Assessment Program (PSAP) 1999-2000; 2007

American Journal of Pharmaceutical Education 1998 – 1999 Renal Failure 1991 – 1994 American Journal of Health Systems Pharmacists 1990 Archives of Pathology 1989 – 1999 Clinical Chemistry 1993 – 1994

Pharmacotherapy Specialty Board 1992 – 1993 NCTRACS Grants PILOT Program 2009

ADVISORY BOARDS

Industry 2012 Novartis Pharmaceuticals 2011 Kaletra Health 2010 Abbott Laboratories/ Abbvie Inc 2009 Novartis Pharmaceuticals 2006 Nabi Biopharmaceuticals 2004 – 2008 Astellas/ Fujisawa Pharmaceuticals 2004 Genzyme Inc 1999 – 2001 Roche Inc 2000 Wyeth-Ayerst Pharmaceuticals 1999 Sidmak Inc. 1998 Sangstat Inc. 1997 – 2003 Astellas/ Fujisawa Pharmaceuticals

Food and Drug Administration

2008 – present Cardio-Renal Advisory Panel, ad hoc member Drug Safety and Monitoring Boards

2012 – present UNC Food Allergy and Immunotherapy Studies – Dr Wesley Burks PI 2013 – present Treatment of HCV Post Liver Transplant Study – Abbvie Inc COMMITTEE APPOINTMENTS AST Community of Pharmacists Transplant Organ Donation Awareness Committee 2009-present

NIH Adult to Adult Living Donor Liver Transplant Consortium Liver Regeneration Subcommittee 2002 - present ACCP Fellowship Committee 2012 – present UNC School of Pharmacy Admissions Committee 2014 - present UNC School of Pharmacy Curricular Transformation Oversight Committee 2013- present UNC DPET Assistant/Associate Professor Search Committee (Chair) 2014 - present UNC School of Pharmacy Scholarship Committee 2011- present UNC DPET Pharmacometrics Program Committee 2010-2012 UNC School of Pharmacy Honors Committee 1999- present (Chair, co-Chair, member) UNC RhoChi Faculty Advisor 2006 – present UNC Student Industry Interest Group Faculty Advisor– 2008- present UNC DPET Fellowship Committee, Director/Chair 2006 – present UNC Renovations Committee 2011-present UNC/UNCH Partnership in Patient Care Acute Care Committee 2011 UNC School of Pharmacy ACPE Accreditation Committee 2010-2011 UNC DPEE Clinical Assistant Professor Search Committee 2010-2011

UNC Healthcare Systems Transplant Outcomes QuaPI Committee 2006- 2012 UNC MSCR UNC-Wilmington New Degree Program Committee 2009

UNC DPET Assistant Professor Search Committee 2007 UNC DPET Clinical Pharmacology Search Committee (Chair ) 2008 UNC DPET Graduate Student PhD Committees 2008-present UNC School of Pharmacy PharmD/PhD Committee 2007 - 2008 UNC School of Pharmacy Faculty Salary Committee 2002 – 2008 UNC School of Pharmacy Admissions and Recruitment Committee 2007 – 2010 UNC Faculty Council 2005 – 2008 UNC School of Pharmacy Scholarship & Awards Committee 1999-2008 UNC DPET Promotion and Reappointment Committee 2002 – 2008 UNC Graduate Student Advisory PhD Committee DPET and MOPH 2002-2006 UNC Graduate Student Advisory PhD Committee DPET and MOPH 2006-2008 UNC Graduate Student Advisory Master's Committee DPET & Division of MOPH 1987– 2003 UNC School of Pharmacy Faculty Development Committee, 1993 – 1998 UNC Ferguson Lecturer Committee (chair) 95-97 ACCP Research Affairs Committee 2008- 2010 ACCP Immunology/ Transplant Program Committee 2001 ACCP Clinical Affairs Committee, 1998 - 2000 ASHP Immunology/ImmunoTherapeutics Fellowship Committee, 1996 – 2000 ACCP Industrial Relations Committee, 1996 – 1997

PROFESSIONAL SOCIETY MEMBERSHIPS

American College of Clinical Pharmacy American Society of Health-System Pharmacy

American Society of Transplantation Triangle Chapter of the American College of Clinical Pharmacy